We analyzed cluster0 KLRG1+EOMES+CD28+ (Fig. 7E,F and Table S5), considering its occurrence in both peripheral blood and tumor site of NSCLC patients, and found a related signature (C0 KLRG1+EOMES+CD28+/Adaptive Immunity), including 11 genes (CD74, PTPRC, ITGA4, KLRG1, CD8A, TRAT1, CD8B, LCK, CD3E, HLA-DMA, HLA-DPA1), associated with improved OS in TCGA-LUAD patients with CD8+PD1+ T-cell enriched tumors (P = 0.0047) (Fig. 8A). This evidence concerns the gene CD74 and neoplasm.